ACBI3 (compound 7) is a pan-KRAS degrader.
ACBI3 achieves in vivo degradation of oncogenic KRAS[1].
[1]. Chuan Zhou, et al. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. J Med Chem. 2022, 65, 5. [Content Brief]